GeorgeKPhilipsMDMBBS, MPH
Oncology • Washington, DCProfessor of Medicine & Vice-Chair (Department of Medicine), Attending Physician in Genitourinary Medical Oncology (Georgetown University Hospital, Washington Cancer Institute and Lombardi Comprehensive Cancer Center)
Dr. Philips is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd Nw
Lombardi Cancer Center
Washington, DC 20007Phone+1 202-444-2223Fax+1 202-444-9429
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 1990 - 1995
Grant Medical CollegeClass of 1986
Certifications & Licensure
DC State Medical License 2010 - 2024
MD State Medical License 2010 - 2013
VT State Medical License 1999 - 2012
CO State Medical License 1990 - 2001- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
- Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Publications & Presentations
PubMed
- 253 citationsTherapeutic uses of anti-PD-1 and anti-PD-L1 antibodiesGeorge Philips, Michael B. Atkins
International Immunology. 2015-01-01 - 5 citationsPhysicians' Perceptions of Factors Influencing the Treatment Decision-making Process for Men With Low-risk Prostate Cancer.Kimberly Davis, Paula G. Bellini, Charlotte J. Hagerman, Riley E. Zinar, Daniel Y. Leigh
Urology. 2017-09-01 - 89 citationsRandomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D. Galsky, Amir Mortazavi, Matthew I. Milowsky, Saby George, Sumati Gupta
Journal of Clinical Oncology. 2020-04-09
Journal Articles
- STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non–Muscle-Invasive Bladder CancerCiaran Mannion, George Philips, Brent T Harris, Pritish Bhattacharyya, Jeffry Simko, Clinical Cancer Research
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
